Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Haemonetics (HAE) Net Cash Flow (2016 - 2025)

Haemonetics has reported Net Cash Flow over the past 17 years, most recently at $66.1 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $66.1 million for Q4 2025, up 138.1% from a year ago — trailing twelve months through Dec 2025 was $35.5 million (down 73.29% YoY), and the annual figure for FY2025 was $128.6 million, up 225.53%.
  • Net Cash Flow for Q4 2025 was $66.1 million at Haemonetics, up from $4.3 million in the prior quarter.
  • Over the last five years, Net Cash Flow for HAE hit a ceiling of $167.1 million in Q2 2024 and a floor of -$160.0 million in Q4 2023.
  • Median Net Cash Flow over the past 5 years was $4.8 million (2021), compared with a mean of $9.1 million.
  • Biggest five-year swings in Net Cash Flow: tumbled 635.35% in 2023 and later skyrocketed 5077.38% in 2024.
  • Haemonetics' Net Cash Flow stood at $19.6 million in 2021, then crashed by 210.9% to -$21.8 million in 2022, then tumbled by 635.35% to -$160.0 million in 2023, then skyrocketed by 117.35% to $27.8 million in 2024, then soared by 138.1% to $66.1 million in 2025.
  • The last three reported values for Net Cash Flow were $66.1 million (Q4 2025), $4.3 million (Q3 2025), and -$18.0 million (Q2 2025) per Business Quant data.